Complications of percutaneous stereotactic vacuum assisted breast biopsy system utilizing radio frequency

Al-Harethee, W.; Theodoropoulos, George; Filippakis, Georgios Michael; Papapanagiotou, Ioannis; Matiatou, Maria; Γεωργίου, Γεωργία; Kalles, Vasileios; Koulocheri, Dimitra; Nonni, Afroditi; Konstadoulakis, Manousos M.; Manouras, Andreas; Zografos, George

doi:10.1016/j.ejrad.2011.12.023

Cited by 19 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results suggested that it might be possible to create the safe follow-up guideline criteria in selected group of patients to avoid unnecessary invasive tissue proved. Although the serious complication of the invasive tissue obtained procedures was minimal, unfortunately the minor complications risk (bleeding, wound infection, pain, or vaso-vagal reactions) were ranged from 0.2-20.14% depended on the reports (Mark, 1991;Steve, 2000;Jacobs, 2001;Medina-Franco, 2005;Tonegutti M 2008;Al-Harethee, 2012).…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcome of Breast Cancer BI-RADS 4 Lesions During 2003-2008 in the National Cancer Institute Thailand

Chaiwerawattana¹,

Thanasitthichai²,

Boonlikit³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

To determine the clinical outcome of breast cancer BI-RADS 4 lesions and seek a more effective management guideline, we conducted a retrospective study of all BI-RADS4 patients diagnosed between 2003-2008 with follow up time not less than 2 years. A total of 392 cases of BI-RADS 4 were identified and 320 could be sub-categorised as 4a, 4b and 4c. Overall malignant positive results were 7.65, 38.7 and 58.percent, respectively. In all cases assigned to the close follow up group, no malignancy was detectable (P<0.02). The results of the study suggested that BI-RADS sub-categories have benefit for cancer diagnosis and treatment decisions of clinicians and it might be possible to set up a safe follow-up guideline in selected groups of patients to minimize un-necessary tissue biopsy for breast cancer detection.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Outcome of Breast Cancer BI-RADS 4 Lesions During 2003-2008 in the National Cancer Institute Thailand

Chaiwerawattana¹,

Thanasitthichai²,

Boonlikit³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…87 Furthermore, concern regarding breast cancer development has been reported to persist in some individuals even 12 months following the receipt of a benign clinical diagnosis. 79,86 Beyond psychological effects, invasive diagnostic procedures such as biopsies can result in post-procedural pain lasting up to 2 weeks in approximately 30% of patients 88 and less often, patients may experience minor haemorrhage 89 and infection, 90 although these complications are very rare. From a financial perspective, diagnostic follow-ups are estimated to cost anywhere from $134.80 USD for additional imaging to $1374.69 USD for invasive diagnostic testing per FP.…”

Section: Risk-benefit Analysis Diagnostic Follow-upmentioning

confidence: 99%

Is the false-positive rate in mammography in North America too high?

Le¹,

Mothersill²,

Seymour³

et al. 2016

BJR

View full text Add to dashboard Cite

The practice of investigating pathological abnormalities in the breasts of females who are asymptomatic is primarily employed using X-ray mammography. The importance of breast screening is reflected in the mortality-based benefits observed among females who are found to possess invasive breast carcinoma prior to the manifestation of clinical symptoms. It is estimated that population-based screening constitutes a 17% reduction in the breast cancer mortality rate among females affected by invasive breast carcinoma. In spite of the significant utility that screening confers in those affected by invasive cancer, limitations associated with screening manifest as potential harms affecting individuals who are free of invasive disease. Disease-free and benign tumour-bearing individuals who are subjected to diagnostic work-up following a screening examination constitute a population of cases referred to as false positives (FPs). This article discusses factors contributing to the FP rate in mammography and extends the discussion to an assessment of the consequences associated with FP reporting. We conclude that the mammography FP rate in North America is in excess based upon the observation of overtreatment of in situ lesions and the disproportionate distribution of detriment and benefit among the population of individuals recalled for diagnostic work-up subsequent to screening. To address the excessive incidence of FPs in mammography, we investigate solutions that may be employed to remediate the current status of the FP rate. Subsequently, it can be suggested that improvements in the breast-screening protocol, medical litigation risk, image interpretation software and the implementation of image acquisition modalities that overcome superimposition effects are promising solutions.

show abstract

“…Five hundred eighteen articles were excluded because they did not use the BLES device or a prototype. We identified 19 full-text versions of studies that used the BLES as a diagnostic or therapeutic device and that fulfilled all the inclusion criteria [4][5][6][7][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Figure 3 shows the results of the study search and identification of eligible studies.…”

Section: Studiesmentioning

confidence: 99%

“…As opposed to other breast biopsy devices, the aim of BLES is to excise and retrieve an intact breast tissue specimen, rather than to obtain fragmented samples [4][5][6][7], which may not only facilitate easier diagnosis but also might allow for minimally invasive resections.…”

Section: Introductionmentioning

confidence: 99%

A systematic review on the use of the Breast Lesion Excision System in breast disease

Sanderink¹,

Laarhuis²,

Strobbe³

et al. 2018

European Journal of Cancer

View full text Add to dashboard Cite

Purpose: To outline the current status of and provide insight into possible future research on the breast lesion excision system (BLES) as a diagnostic and therapeutic device. Methods: A systematic search of the literature was performed using PubMed, Embase, and the Cochrane databases to identify relevant studies published between January 2002 and April 2018. Studies were considered eligible for inclusion if they evaluated the diagnostic or therapeutic accuracy or safety of BLES. Results: Ultimately, 17 articles were included. The reported underestimation rates of atypical ductal hyperplasia and ductal carcinoma in situ (DCIS) ranged from 0 to 14.3% and from 0 to 22.2%, respectively. Complete excision rates for invasive ductal carcinoma and DCIS ranged from 5.3 to 76.3%. Bleeding was the most frequently reported complication (0-11.8%). Device-related complications may arise, with an empty basket being the most common (0.6-3.6%). Thermal damage of the specimen, caused by the use of a radiofrequency cutting wire, was reported in eight of the included studies. Most thermal artifacts were reported as superficial and small (0.1-1.9 mm). Conclusions: The BLES, an automated, image-guided, single-pass biopsy system for breast lesions using radiofrequency is designed to excise and retrieve an intact tissue specimen. It is an efficient and safe breast biopsy method with acceptable complication rates, which may be used as an alternative to vacuum-assisted biopsies. The variable rate of complete excision raises questions about the possibility to use BLES as a therapeutic device for the excision of small lesions. Further research should focus on this aspect of BLES.

show abstract

Complications of percutaneous stereotactic vacuum assisted breast biopsy system utilizing radio frequency

Cited by 19 publications

References 19 publications

Clinical Outcome of Breast Cancer BI-RADS 4 Lesions During 2003-2008 in the National Cancer Institute Thailand

Clinical Outcome of Breast Cancer BI-RADS 4 Lesions During 2003-2008 in the National Cancer Institute Thailand

Is the false-positive rate in mammography in North America too high?

A systematic review on the use of the Breast Lesion Excision System in breast disease

Contact Info

Product

Resources

About